Biopharmaceutical Companies Merge and Present at Conferences

LENZ Therapeutics and Graphite Bio have announced a merger agreement to create a biopharmaceutical company focused on advancing LENZ Therapeutics lead assets for the treatment of presbyopia. Opthea, a biopharmaceutical company, will present at the Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference. Opthea has appointed Frederic Guerard as CEO and Peter Lang as CFO. The company will also participate in the 2023 Euretina Congress and feature its lead product candidate, OPT-302, at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting.